Researchers found that the dual peroxisome proliferator-activated receptor alpha/delta agonist Elafibranor (ELA) exerts a hepatoprotective effect by reducing cleaved RIPK3 and cleaved caspase-3, which in turn reduced hepatocyte necroptosis and apoptosis, inhibited hepatic steatosis, inflammation, and fibrosis, resulting in significantly lowered NASs [70]. Here, RIPK3 is linked to Hepatic steatosis.